Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Confirms Data for Phase 2a Alzheimer’s Trial for ANAVEX 2-73

November 11, 2015

Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease‎

November 9, 2015

Anavex Announces CTAD 2015 Abstract

November 5, 2015

Anavex Commences Trading on NASDAQ Today – To Ring Friday’s Closing Bell

October 28, 2015

Anavex Announces Uplisting to NASDAQ

October 26, 2015

Anavex to Present at 4th Annual OktoberINVESTfest Conference

October 12, 2015

Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference

October 7, 2015

Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split

October 6, 2015

Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule

September 28, 2015

Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference

September 23, 2015

Anavex Appoints International Alzheimer’s Expert to Scientific Advisory Board

September 21, 2015

Anavex Reports Fiscal Third Quarter 2015 Financial Results

August 17, 2015
1
23456789101112131415
…1617181920…
212223242526272829303132333435363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top